Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles

2018, Global, regional, national age-sex-specific mortality for 282 causes of death in 195 countries, territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet., 392, 1736, 10.1016/S0140-6736(18)32203-7 INE. Defunciones por causas (lista reducida) por sexo y grupos de edad (7947). INE [consultado 16 Feb 2022]. Disponible en: https://www.ine.es/jaxiT3/Datos.htm?t=7947#!tabs-tabla Borén, 2020, Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel, Eur Heart J., 41, 2313, 10.1093/eurheartj/ehz962 Royo Bordonada, 2011, Dislipidemias: un reto pendiente en prevención cardiovascular. Documento de consenso CEIPC/SEA, Med Clin (Barc)., 137, 30.e1, 10.1016/j.medcli.2011.02.008 De Backer, 2019, Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries, Atherosclerosis., 285, 135, 10.1016/j.atherosclerosis.2019.03.014 Ray, 2021, EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study, Eur J Prev Cardiol., 28, 1279, 10.1093/eurjpc/zwaa047 González-Juanatey, 2011, Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain, DYSIS-Spain Study, Rev Esp Cardiol (Engl Ed)., 64, 286, 10.1016/j.recesp.2010.10.030 Robinson, 2016, Determining When to Add Nonstatin Therapy: A Quantitative Approach, J Am Coll Cardiol., 68, 2412, 10.1016/j.jacc.2016.09.928 Visseren, 2021, Eur Heart J., 42, 3227, 10.1093/eurheartj/ehab484 Visseren, 2022, Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica: Con la contribución especial de la European Association of Preventive Cardiology (EAPC), Rev Esp Cardiol., 75, 429.e1, 10.1016/j.recesp.2021.10.016 Palacio-Portilla, 2022, Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología, Neurologia., 37, 61, 10.1016/j.nrl.2020.07.027 Mostaza, 2022, Estándares SEA 2022 para el control global del riesgo cardiovascular, Clin Investig Arterioscler., 34, 130 Armario, 2021, Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines, Clin Investig Arterioscler., 33, 85 Pedro-Botet, 2018, Homogeneización de los valores del perfil lipídico, Clin Investig Arterioscler., 30, 36 Pedro-Botet, 2018, El informe analítico ideal del perfil lipídico. Necesidad de un consenso, Rev Esp Cardiol., 71, 512, 10.1016/j.recesp.2018.01.004 Wright, 1976, Correct Levels of Serum Cholesterol: Average vs Normal vs Optimal, JAMA., 236, 261, 10.1001/jama.1976.03270030015018 Nordestgaard, 2020, Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM, Atherosclerosis., 294, 46, 10.1016/j.atherosclerosis.2019.12.005 Wilson, 2021, Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group, J Clin Lipidol., 15, 629, 10.1016/j.jacl.2021.09.046 Cooper, 1992, Blood Lipid Measurements: Variations and Practical Utility, JAMA., 267, 1652, 10.1001/jama.1992.03480120090039 Bays, 2016, National Lipid Association Annual Summary of Clinical Lipidology 2016, J Clin Lipidol., 10, S1, 10.1016/j.jacl.2015.08.002 Herink, 2000, Medication Induced Changes in Lipid and Lipoproteins Khovidhunkit, 2004, Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host, J Lipid Res., 45, 1169, 10.1194/jlr.R300019-JLR200 Feingold, 2000, The Effect of Inflammation and Infection on Lipids and Lipoproteins van Leeuwen, 2003, Lipoprotein metabolism in patients with severe sepsis, Crit Care Med., 31, 1359, 10.1097/01.CCM.0000059724.08290.51 Páez-Guillán, 2021, Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis, Lipids Health Dis., 20, 177, 10.1186/s12944-021-01603-9 Shrivastava, 2015, Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction, EXCLI J., 14, 517 Wattanasuwan, 2001, Effect of Acute Myocardial Infarction on Cholesterol Ratios, Chest., 120, 1196, 10.1378/chest.120.4.1196 Rosenson, 1993, Myocardial injury: the acute phase response and lipoprotein metabolism, J Am Coll Cardiol., 22, 933, 10.1016/0735-1097(93)90213-K Enkhmaa, 2016, Lipoprotein (a): impact by ethnicity and environmental and medical conditions, J Lipid Res., 57, 1111, 10.1194/jlr.R051904 Langsted, 2014, Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular risk, Atherosclerosis., 234, 95, 10.1016/j.atherosclerosis.2014.01.049 Nordestgaard, 2016, Eur Heart J., 37, 1944, 10.1093/eurheartj/ehw152 Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events, Circulation., 118, 993, 10.1161/CIRCULATIONAHA.108.777334 Martin, 2013, Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile, JAMA., 310, 2061, 10.1001/jama.2013.280532 Martin, 2013, Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications, J Am Coll Cardiol., 62, 732, 10.1016/j.jacc.2013.01.079 Sniderman, 2011, A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk, Circ Cardiovasc Qual Outcomes., 4, 337, 10.1161/CIRCOUTCOMES.110.959247 Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J., 41, 111, 10.1093/eurheartj/ehz455 Arnett, 2019, 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation., 140, e596 Grundy, 2019, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation., 139, e1082 Pearson, 2021, 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults, Can J Cardiol., 37, 1129, 10.1016/j.cjca.2021.03.016 Langlois, 2020, Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM, Clin Chem Lab Med., 58, 496, 10.1515/cclm-2019-1253 Marston, 2022, Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content, JAMA Cardiol., 7, 250, 10.1001/jamacardio.2021.5083 2021, CORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe, Eur Heart J., 42, 2439, 10.1093/eurheartj/ehab309 2021, SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions, Eur Heart J., 42, 2455, 10.1093/eurheartj/ehab312 Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA., 302, 1993, 10.1001/jama.2009.1619 Richardson, 2020, Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis, PLoS Med., 17, e1003062, 10.1371/journal.pmed.1003062 Pintó, 2020, Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®), Clin Investig Arterioscler., 32, 219 1999 Paquette, 2020, A simplified diagnosis algorithm for dysbetalipoproteinemia, J Clin Lipidol., 14, 431, 10.1016/j.jacl.2020.06.004 Wilson, 2019, Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association, J Clin Lipidol., 13, 374, 10.1016/j.jacl.2019.04.010 Reyes-Soffer, 2021, Lipoprotein(a): A Genetically Determined Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association, Arterioscler Thromb Vasc Biol., 42, e48 Cegla, 2019, HEART UK consensus statement on Lipoprotein(a): A call to action, Atherosclerosis., 291, 62, 10.1016/j.atherosclerosis.2019.10.011 Kronenberg, 2022, Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, Eur Heart J., 43, 3925, 10.1093/eurheartj/ehac361 Burgess, 2018, Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis, JAMA Cardiol., 3, 619, 10.1001/jamacardio.2018.1470 Langsted, 2016, High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study, Lancet Diabetes Endocrinol., 4, 577, 10.1016/S2213-8587(16)30042-0 Ascaso, 2019, Indicaciones de los inhibidores de proproteína convertasa subtilisina kexina 9 (PCSK9) en la práctica clínica, Clin Investig Arterioscler., 31, 128 Conrad, 2022, Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK, The Lancet., 400, 733, 10.1016/S0140-6736(22)01349-6 Moulin, 2018, Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an «FCS score», Atherosclerosis., 275, 265, 10.1016/j.atherosclerosis.2018.06.814